Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine - Eli Lilly and Company/Genentech

Drug Profile

Gemcitabine - Eli Lilly and Company/Genentech

Alternative Names: dFdC; dFdCTP; Gemtro; Gemzar; LY 188011

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Genentech; University of Innsbruck
  • Developer Cancer Research UK; Eli Lilly and Company; Genentech; Mayo Clinic; National Cancer Institute (USA); University of Iowa
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Phase II Lymphoma; Renal cell carcinoma; Salivary gland cancer
  • Phase I/II Sarcoma
  • No development reported Head and neck cancer; Solid tumours

Most Recent Events

  • 17 Nov 2017 Roche plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia, South Korea, France, Spain, United Kingdom and USA in December 2017 (NCT03337698)
  • 14 Nov 2017 Roche initiates enrolment in a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia (IV) (NCT03337698)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in Germany (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top